HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.

AbstractOBJECTIVES:
Pancreatic adenocarcinoma is a deadly disease with an overall 5-year patient survival of less than 5%. This dismal prognosis of pancreatic cancer is largely due to the advanced stage of the disease at presentation. If pancreatic cancer could be diagnosed more readily and accurately using serum markers, patient survival could theoretically be improved by enabling more patients to avail of surgical resection. One candidate tumor marker recently identified by global gene expression analysis of pancreatic cancer is the secreted glycophosphoprotein osteopontin (OPN). In this study, we evaluate OPN as a serum marker of pancreatic adenocarcinoma.
METHODS:
In situ hybridization for OPN was performed on a pancreatic adenocarcinoma tissue microarray. Serum OPN levels were determined in preoperative sera from 50 patients with pancreatic cancer and 22 healthy control individuals by competitive ELISA.
RESULTS:
In situ hybridization for OPN performed on a tissue microarray revealed strong OPN mRNA signal in tumor-infiltrating macrophages in 8 of 14 pancreatic adenocarcinomas. In contrast, OPN expression was not seen in the pancreatic cancer cells themselves, nor was it seen in normal pancreatic tissue or in the macrophages distant from the infiltrating cancer. Serum OPN levels, as measured by ELISA, were elevated in the sera of 50 patients with resectable pancreatic adenocarcinoma compared to 22 healthy control individuals (mean +/- SD for OPN was 482 +/- 170 ng/ml and 204 +/- 65 ng/ml, respectively; P < 0.001). Using a cutoff level of 2 SD above the mean for healthy individuals, elevated OPN had sensitivity of 80% and specificity of 97% for pancreatic cancer. In contrast, only 62% of these patients with resectable pancreatic cancer had elevated CA19-9.
CONCLUSIONS:
Serum OPN may have utility as a diagnostic marker in patients with pancreatic cancer.
AuthorsJens Koopmann, Neal S Fedarko, Alka Jain, Anirban Maitra, Christine Iacobuzio-Donahue, Ayman Rahman, Ralph H Hruban, Charles J Yeo, Michael Goggins
JournalCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (Cancer Epidemiol Biomarkers Prev) Vol. 13 Issue 3 Pg. 487-91 (Mar 2004) ISSN: 1055-9965 [Print] United States
PMID15006928 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Biomarkers, Tumor
  • SPP1 protein, human
  • Sialoglycoproteins
  • Osteopontin
Topics
  • Adenocarcinoma (pathology)
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor (analysis)
  • Case-Control Studies
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Gene Expression Profiling
  • Humans
  • In Situ Hybridization
  • Macrophages
  • Male
  • Middle Aged
  • Oligonucleotide Array Sequence Analysis
  • Osteopontin
  • Pancreatic Neoplasms (pathology)
  • Sensitivity and Specificity
  • Sialoglycoproteins (analysis, biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: